FDA Considers Stricter Rules for Direct-to-Consumer Drug Advertising
The Food and Drug Administration (FDA) is proposing stricter regulations for direct-to-consumer (DTC) prescription drug advertisements. In its 2027 budget request, the FDA seeks authority to designate prescription drugs as 'misbranded' under the Federal Food, Drug, and Cosmetic (FD&C) Act if their DTC ads lack 'fair balance' or create a misleading impression regarding FDA approval, the scope of approved indications, limitations of use, or the drug's efficacy and benefits. This builds on a 1969 regulation requiring broadcast drug ads to present risks and benefits in a clear, conspicuous, and neutral manner. Additionally, the FDA has proposed eliminating the 'adequate provision' standard, which currently allows broadcast ads to direct consumers to other sources for full risk information. The new proposal, included in the 2026 Regulatory Plan, would require broadcast ads to disclose all relevant risk and safety information within the ad itself.